Cyclosporine (eye drops)

A calcineurin inhibitor eye drop, FDA-approved to increase tear production in dry eye (keratoconjunctivitis sicca) and treat dry eye signs and symptoms.

psilodex.org/m/cyclosporine-ophthalmic · data v2026.10.04

Clinical contraindication: None listed; No clinical contraindication identified.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references; Not applicable in practice: blood levels are below or near the 0.1 ng/mL quantitation limit after eye-drop use.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Cyclosporine (eye drops)”, v2026.10.04. psilodex.org/m/cyclosporine-ophthalmic

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

FDA-approved for

Dry eye disease (keratoconjunctivitis sicca): increasing tear production; signs and symptoms of dry eye

Sources [1][2][3]

01 Interaction with psilocybin

No known interaction with psilocybin; labels report blood levels after eye-drop use at or below the lower limit of measurement.

Detail No known interaction. Labels report blood cyclosporine below or just above the assay limit (0.1 ng/mL) after eye-drop dosing, so the blood pressure and seizure warnings for oral cyclosporine describe a much higher exposure. Sources [1][2][3]

No reported interaction is not a finding of safety: most combinations with psilocybin have never been studied.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

No psilocybin dataNo psilocybin data; record based on general references (product label, reference works, reviews)

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

RESTASIS (cyclosporine ophthalmic emulsion) 0.05% (Allergan) · FDA label (DailyMed) — revised 2024-09-09 | interaction: "Blood concentrations of cyclosporine, in all the samples collected, after topical administration of RESTASIS 0.05%, twice daily, in humans for up to 12 months, were below the quantitation limit of 0.1 ng/mL."
CEQUA (cyclosporine ophthalmic solution) 0.09% (Sun Pharma) · FDA label (DailyMed) — revised 2026-06-15 | interaction: "were either not detectable or were marginally above the lower limit of assay quantitation of 0.100 ng/mL"
VEVYE (cyclosporine ophthalmic solution) 0.1% (Harrow Eye) · FDA label (DailyMed) — revised 2026-02-26 | interaction: "the blood concentrations of cyclosporine were below the limit of quantification (0.1 ng/mL) at all timepoints."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-03Last reviewed against its sources.

Report an error in this record →